Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced on [date not provided] the completion of its first export of naturally derived psilocybin to the United Kingdom, supporting a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company’s GMP facility in Princeton, British Columbia.
According to the company, the capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression. The export was authorized by Health Canada and the UK Home Office, underscoring the growing regulatory acceptance of psychedelic compounds for mental health research. Optimi noted that the products were cultivated, extracted, and manufactured in-house under its Drug Establishment Licence, reinforcing its position as a vertically integrated GMP supplier serving both regulated patient access programs and clinical research initiatives.
This development is significant for the psychedelic medicine industry as it demonstrates the ability to navigate complex international shipping regulations. The UK trial could provide critical data on the efficacy of psilocybin for mental health conditions, potentially accelerating approvals and expanding access. For Optimi, this export validates its manufacturing capabilities and opens the door to future commercial partnerships.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia. The company supplies active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information, visit Optimi Health or optimi.net. The full press release is available at this link.
